Atlas Trials

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Clinical trial NCT03313661 · UNKNOWN

Trial details

NCT number
NCT03313661
Sponsor
Sherief Abd-Elsalam
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes
Start date
2017-10-14
Primary completion
2020-10-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.